Comprehensive prognostic report of the Japanese Breast Cancer Society Registry in 2004

Kinoshita, Takayuki; Fukui, Naohito; Anan, Keisei; Inomata, Takayuki; Niikura, Naoki; Kawai, Masaaki; Hayashi, Naoki; Tsugawa, Kouichiro; Aogi, Kenjiro; Ishida, Toru; Masuoka, Hideji; Masuda, Shinobu; Iijima, Kotaro; Nakamura, Seigo; Tokuda, Yutaka

doi:10.1007/s12282-015-0644-5

Cited by 5 publications

(4 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…First, the relatively short follow-up period (median 4.5 years), which limited the power of the survival analysis. Nevertheless, prognostic analyses from this database that have previously been published were relatively consistent with the well-known consensus and clinical outcomes [ 36 – 38 ]. Second, during the study period, trastuzumab (which should exert a favourable effect on HER2-positive breast cancers) had not been widely prescribed as the standard agent and was only partially received.…”

Section: Discussionsupporting

confidence: 57%

Young adult breast cancer patients have a poor prognosis independent of prognostic clinicopathological factors: a study from the Japanese Breast Cancer Registry

Kataoka

Inomata

Tokunaga

et al. 2016

Breast Cancer Res Treat

Self Cite

View full text Add to dashboard Cite

PurposeThe aim of this study was to investigate whether young age at onset of breast cancer is an independent prognostic factor in patients from the Japanese Breast Cancer Registry, after adjustment of known clinicopathological prognostic factors.MethodsOf the 53,670 patients registered between 2004 and 2006 and surveyed after a 5-year follow-up prognosis, 25,898 breast cancer patients (48.3 %), who were obtained prognostic data, were examined. Clinicopathological factors were compared between young adult (YA; <35 years), middle-aged adult (MA; 35–50 years), and older adult (OA; >50 years) patients. Five-year disease-free survival (DFS) and overall survival (OS) rates were studied.ResultsYA patients were associated with an advanced TNM stage and aggressive characteristics (e.g. human epidermal growth factor receptor 2 (HER2)-positive or oestrogen receptor (ER)-negative breast cancers) compared to MA and OA patients (P < 0.001). The 5-year DFS and OS rates were 79.4 % and 90.8, 88.5 and 95.0 %, and 87.8 % and 91.6 % for YA, MA, and OA patients, respectively. From the multivariable regression analysis, young age at onset was confirmed as an independent prognostic factor for both DFS (hazard ratio 1.73, 95 % confidence interval 1.42–2.10; P < 0.001) and OS (hazard ratio 1.58, 95 % confidence interval 1.16–2.15; P = 0.004).ConclusionsYoung age at onset is an independent negative prognostic factor in breast cancer. Further studies are required to develop new therapeutic strategies for YA breast cancer patients.Electronic supplementary materialThe online version of this article (doi:10.1007/s10549-016-3984-8) contains supplementary material, which is available to authorized users.

show abstract

Section: Discussionsupporting

confidence: 57%

Young adult breast cancer patients have a poor prognosis independent of prognostic clinicopathological factors: a study from the Japanese Breast Cancer Registry

Kataoka

Inomata

Tokunaga

et al. 2016

Breast Cancer Res Treat

Self Cite

View full text Add to dashboard Cite

show abstract

“…In the present study, all but one of the patients were female, and their median age was 43 years. In previous reports, the median age at diagnosis of patients with gastric cancer with breast metastasis was 46 years ( 9 ), and for patients with primary breast cancer was 61 years in the USA and 56.99 years in Japan ( 72 , 73 ). Breast metastases originating from gastric carcinoma tend to occur at younger ages than primary breast carcinomas ( 9 ).…”

Section: Discussionmentioning

confidence: 97%

Gastric cancer with breast metastasis: Clinical features and prognostic factors

Liu

et al. 2018

Oncol Lett

View full text Add to dashboard Cite

Metastatic spread of gastric carcinoma to the breast is rare. In previous decades, reports on this subject were minimal and primarily limited to case reports. At present, little is known on the clinicopathological features and prognosis of this condition, and breast metastasis remains a challenging clinical problem. A total of 54 cases of breast metastasis from gastric cancer were collected from databases between January 1960 and December 2016. The present study included 3 cases of gastric cancer with breast metastasis from Renji hospital and 51 additional cases from previous studies. The clinicopathological features of patients, including epidemiology, symptoms, macroscopic presentation, pathological diagnosis, imaging, treatment and overall survival time, were analyzed. The median survival time was 8.6 months. All but one of the patients were female, and the median age at diagnosis of breast metastasis was 43 years old (age range, 22–72 years). A majority of patients presented with Borrmann class III disease, signet ring cell carcinoma, T4 tumor types, lymph node involvement, initial stage IV gastric cancer, primary lesions in the gastric antrum, left breast metastasis and palpable breast nodules. The median interval between the primary gastric carcinoma diagnosis and presentation of breast metastasis was 1.25 months (range, 0–72 months). The expression of the estrogen receptor, progesterone receptor, human epidermal growth factor receptor-2 and gross cystic disease fluid protein-15 was negative in the patients with breast metastases. In univariate analysis, age, gastric tumor size, gastric lymph node involvement and breast metastasis histology were significantly associated with overall survival (OS) time (P=0.001, 0.039, 0.034 and <0.001, respectively). Therapeutically, gastric surgery and chemotherapy were not associated with OS (P=0.959 and 0.290, respectively). In further multivariate analysis, the time between occurrence (P=0.017), age (P=0.009), histology (P=0.045) and breast metastasis localization (P=0.043) were independent indicators of OS time. Although breast metastasis from gastric cancer is rare, physicians should be vigilant when patients with a history of gastric cancer present with newly developed mammary symptoms and signs.

show abstract

“…This may be another reason for the increasing numbers of DCIS during our study period in Japan [ 22 ]. DCIS have an extremely favorable prognosis after surgery [ 23 – 25 ], although the natural course of DCIS remains unclear. Small retrospective studies showed that some cases may progress to invasive breast cancers in the absence of any therapeutic interventions, whereas others do not.…”

Section: Discussionmentioning

confidence: 99%

Distinct breast cancer characteristics between screen- and self-detected breast cancers recorded in the Japanese Breast Cancer Registry

Inomata

Kumamaru

Matsubara

et al. 2016

Breast Cancer Res Treat

Self Cite

View full text Add to dashboard Cite

The rate of breast cancer screening for women of all ages in Japan is increasing. However, little is known about the biological differences between screen- and self-detected tumors. We used data from the Japanese Breast Cancer Registry (JBCR), a nationwide registry of newly diagnosed breast cancer cases in Japan, to investigate patients diagnosed between January 1, 2004 and December 31, 2011. We compared the clinicopathological features of tumors and assessed yearly trends regarding the proportion of screen-detected cases during the study period. We found that 31.8 % (65,358/205,544) of cancers were detected by screening. Asymptomatic tumors detected by screening (asymptomatic) were more likely to have favorable prognostic features than those that were self-detected (ductal carcinoma in situ [DCIS]: 19.8 versus 4.1 %, node-negative: 77.0 versus 61.6 %, and estrogen receptor-positive [ER+]: 82.0 versus 72.9 %, respectively). All these findings were statistically significant (p < .001). The proportion of breast cancers detected by screening among all cases increased from 21.7 % in 2004 to 37.1 % in 2011. During the same time period, the proportion of screen-detected DCIS increased from 41.5 to 66.0 % and that of ER+ cancers increased from 23.2 to 39.7 %. This study demonstrated that low-risk tumors, including DCIS, ER+, and lower TNM stage, account for a substantial proportion of clinical screening-detected cancers. The differences in biological characteristics between screen- and self-detected cancers may account in part for the limited efficacy of breast cancer screening programs aimed at improving breast cancer mortality.Electronic supplementary materialThe online version of this article (doi:10.1007/s10549-016-3770-7) contains supplementary material, which is available to authorized users.

show abstract

Comprehensive prognostic report of the Japanese Breast Cancer Society Registry in 2004

Cited by 5 publications

References 1 publication

Young adult breast cancer patients have a poor prognosis independent of prognostic clinicopathological factors: a study from the Japanese Breast Cancer Registry

Young adult breast cancer patients have a poor prognosis independent of prognostic clinicopathological factors: a study from the Japanese Breast Cancer Registry

Gastric cancer with breast metastasis: Clinical features and prognostic factors

Distinct breast cancer characteristics between screen- and self-detected breast cancers recorded in the Japanese Breast Cancer Registry

Contact Info

Product

Resources

About